China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
Tenax Therapeutics, Inc. (NASDAQ:TENX) CEO Christopher Thomas Giordano, recently purchased shares of the company’s common stock, according to a Form 4 filing with the Securities and Exchange Commission.
Between November 18 and November 20, 2025, Giordano acquired a total of 2,605 shares through three transactions. The purchases, were executed at prices ranging from $7.5091 to $7.7546, totaling $19,999.
In addition, the report detailed holdings of stock options (right to buy) with various exercise prices and expiration dates, relating to the acquisition of Tenax Therapeutics, Inc. (NASDAQ:TENX) common stock.
In other recent news, Piper Sandler has initiated coverage on Tenax Therapeutics with an Overweight rating, setting a price target of $20.00. This development highlights the firm’s focus on Tenax’s ongoing research and development efforts. Specifically, Piper Sandler pointed to Tenax’s work on TNX-103, an oral treatment for pulmonary hypertension with heart failure with preserved ejection fraction. The Phase 3 LEVEL trial results for this treatment are anticipated in the second half of 2026. These recent developments reflect the company’s ongoing commitment to advancing its therapeutic pipeline. Piper Sandler’s positive outlook may be of interest to investors monitoring Tenax’s progress in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.